chronic heart failure, chronic kidney disease
Conditions
Interventions
Tolvaptan group: Add tolvaptan administration
Furosemide group: Increased furosemide administration
Sponsors
Kawashima hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Heart failure patients over 20 years of age taking over 40 mg/day furosemide with a estimated GFR (eGFR)<45 mL/min/1.73m2.
Exclusion criteria
Exclusion criteria: Patients who cannot intake fluids or feel thirst Patients with anuria or urinary excretion disorder Patients with hypernatremia Patients with serious hepatic disorder Patients under the pacing therapy Patients with percutaneous coronary intervention or open heart surgery within the past 3 months Patients with poorly controlled diabetes mellitus Patients who take SGLT-2 inhibitor Patients who are pregnant or possibly pregnant Patients without agreement on enrolment of this study Inappropriate patients judged by doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum creatinine level eGFR change from baseline Worsening renal function (WRF) from 1 days to 1 years later Days until the dialysis induction Dialysis induction rate | — |
Secondary
| Measure | Time frame |
|---|---|
| urine volume, body weight, blood pressure, heart rate, plasma BNP, echocardiography (inferior vena cava diameters, ejection fraction), chest X ray (cardio-thoracic ratio, pulmonary congestion), urine osmolality, Fractional Excretion of Na (FENa), serum BUN, serum Na, serum K , New York heart association cardiac functional classification, cardiovascular event rate | — |
Countries
Japan
Contacts
Public ContactHisato Shima
Kawashima hospital Department of Kidney Disease
Outcome results
None listed